Moravej, Fahimeh Ghasemi http://orcid.org/0000-0003-3878-3082
Amini, Abdollah http://orcid.org/0000-0002-9408-3200
Masteri Farahani, Reza http://orcid.org/0000-0001-6721-2153
Mohammadi-Yeganeh, Samira http://orcid.org/0000-0001-8921-4045
Mostafavinia, Atarodalsadat http://orcid.org/0000-0003-2270-5637
Ahmadi, Houssein http://orcid.org/0000-0002-6300-4143
Omidi, Hamidreza http://orcid.org/0000-0001-8748-1270
Rezaei, Fatemehalsadat http://orcid.org/0000-0001-5699-9907
Gachkar, Latif http://orcid.org/0000-0002-5314-5022
Hamblin, Michael R http://orcid.org/0000-0001-6431-4605
Chien, Sufan http://orcid.org/0000-0002-1067-4178
Bayat, Mohammad http://orcid.org/0000-0001-5214-4223
Funding for this research was provided by:
Shahid Beheshti University of Medical Sciences (25918)
Article History
Received: 19 October 2022
Accepted: 12 May 2023
First Online: 27 May 2023
Declarations
:
: Not applicable
: Michael R Hamblin declares the following potential conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; Hologenix Inc. Santa Monica, CA; Vielight, Toronto, Canada; JOOVV Inc, Minneapolis-St. Paul MN; Sunlighten, Kansas City, MO; Consulting; USHIO Corp, Japan; Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany; Klox Asia, Guangzhou, China. Stockholding: Niraxx Light Therapeutics, Inc, Irvine CA; JelikaLite Corp, New York NY. The other authors report they have no conflicts of interest.